Inhibikase Therapeutics, INC. (IKT) — SEC Filings

Overview

Inhibikase Therapeutics, INC. (IKT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 7, 2026: Inhibikase Therapeutics, Inc. filed an 8-K on April 7, 2026, reporting under Regulation FD Disclosure and Financial Statements and Exhibits. The filing includes an exhibit (EX-99.1) and an extracted XBRL instance document, indicating potential updates or disclosures related to the company's financia

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 1 bearish, 47 neutral, 2 mixed. The dominant filing sentiment for Inhibikase Therapeutics, INC. is neutral.

Filing Type Overview

Inhibikase Therapeutics, INC. (IKT) has filed 20 8-K, 1 S-8, 3 10-K, 6 10-Q, 2 DEFA14A, 4 DEF 14A, 1 10-K/A, 7 SC 13G, 2 S-1, 3 S-1/A, 1 8-K/A with the SEC between Mar 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• Inhibikase Therapeutics Files 8-K — 8-K · Apr 7, 2026 Risk: medium
  Inhibikase Therapeutics, Inc. filed an 8-K on April 7, 2026, reporting under Regulation FD Disclosure and Financial Statements and Exhibits. The filing includes
• Inhibikase Therapeutics Files S-8 for Employee Stock Plans — S-8 · Mar 26, 2026 Risk: low
  Inhibikase Therapeutics, Inc. filed an S-8 registration statement on March 26, 2026, to register securities to be offered under its employee benefit plans. This
• Inhibikase Kicks Off Phase 3 for PAH Drug IKT-001, Eyes $8.3B Market — 10-K · Mar 26, 2026 Risk: high
  Inhibikase Therapeutics, Inc. (IKT) is a clinical-stage pharmaceutical company focused on cardiopulmonary diseases, particularly Pulmonary Arterial Hypertension
• 8-K Filing — 8-K · Dec 19, 2025
• 8-K Filing — 8-K · Nov 21, 2025
• Inhibikase Therapeutics Files 8-K Report — 8-K · Nov 20, 2025 Risk: low
  On November 20, 2025, Inhibikase Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 1000 N. W
• Inhibikase Losses Mount Amid Soaring R&D for PAH Drug — 10-Q · Nov 14, 2025 Risk: high
  Inhibikase Therapeutics, Inc. (IKT) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $35,524,538, compared to
• Inhibikase Losses Soar 145% on R&D Boost, Cash Position Strong — 10-Q · Aug 14, 2025 Risk: high
  Inhibikase Therapeutics, Inc. (IKT) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $23,594,258, a substantial rise
• Inhibikase Therapeutics Reports Shareholder Vote — 8-K · Jun 30, 2025 Risk: medium
  Inhibikase Therapeutics, Inc. filed an 8-K on June 30, 2025, reporting on a matter submitted to a vote of its security holders on June 27, 2025. The filing does
• Inhibikase Therapeutics Files Proxy Statement Supplement — DEFA14A · Jun 12, 2025 Risk: low
  Inhibikase Therapeutics, Inc. filed a Definitive Additional Materials filing (DEFA14A) on June 12, 2025. This filing supplements their proxy statement, indicati
• Inhibikase Therapeutics Files 8-K on Financials — 8-K · May 14, 2025 Risk: low
  Inhibikase Therapeutics, Inc. filed an 8-K on May 14, 2025, reporting on its results of operations and financial condition. The filing includes financial statem
• Inhibikase Therapeutics Files Q1 2025 10-Q — 10-Q · May 14, 2025 Risk: medium
  Inhibikase Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition and business operations, incl
• Inhibikase Therapeutics Files 2025 Proxy Statement — DEF 14A · May 12, 2025 Risk: low
  Inhibikase Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on May 12, 2025, for its annual meeting on June 27, 2025. The filing concerns the s
• Inhibikase Therapeutics Files 10-K/A Amendment — 10-K/A · Apr 25, 2025 Risk: low
  Inhibikase Therapeutics, Inc. filed an amendment (10-K/A) on April 25, 2025, for their fiscal year ending December 31, 2024. The company, located in Atlanta, GA
• Inhibikase Therapeutics Announces Corporate Changes — 8-K · Apr 14, 2025 Risk: medium
  Inhibikase Therapeutics, Inc. announced on April 11, 2025, a series of significant corporate actions. These include the departure of certain officers and direct
• Inhibikase Therapeutics Files 8-K on Financials — 8-K · Mar 27, 2025 Risk: low
  Inhibikase Therapeutics, Inc. filed an 8-K on March 27, 2025, reporting on its results of operations and financial condition. The filing also includes financial
• Inhibikase Therapeutics Files 2024 10-K — 10-K · Mar 27, 2025 Risk: medium
  Inhibikase Therapeutics, Inc. filed its 2024 10-K on March 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on biological p
• Inhibikase Therapeutics Files 8-K with Key Corporate Updates — 8-K · Feb 24, 2025 Risk: medium
  Inhibikase Therapeutics, Inc. announced on February 21, 2025, the entry into a material definitive agreement. The company also reported on unregistered sales of
• Inhibikase Therapeutics Files 8-K on Officer/Director Changes — 8-K · Feb 18, 2025 Risk: medium
  Inhibikase Therapeutics, Inc. filed an 8-K on February 18, 2025, reporting events as of February 13, 2025. The filing covers the departure of directors or certa
• Inhibikase Therapeutics Files 8-K Report — 8-K · Jan 29, 2025 Risk: low
  On January 29, 2025, Inhibikase Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and does not detail specific transactions o
• Inhibikase Therapeutics Files 8-K — 8-K · Jan 6, 2025 Risk: low
  Inhibikase Therapeutics, Inc. filed an 8-K on January 6, 2025, reporting events that occurred on January 3, 2025. The filing indicates amendments to its Article
• Inhibikase Therapeutics Terminates Material Agreement — 8-K · Dec 5, 2024 Risk: medium
  Inhibikase Therapeutics, Inc. announced on December 2, 2024, the termination of a material definitive agreement. The company, incorporated in Delaware, is based
• Inhibikase Therapeutics Files 2025 Proxy Statement — DEF 14A · Nov 18, 2024 Risk: medium
  Inhibikase Therapeutics, Inc. filed its definitive proxy statement on November 18, 2024, for its 2025 annual meeting of stockholders, which is scheduled for Jan
• SC 13G Filing — SC 13G · Nov 14, 2024
• Inhibikase Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: medium
  Inhibikase Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial condition and results of operations
• SC 13G Filing — SC 13G · Oct 28, 2024
• SC 13G Filing — SC 13G · Oct 28, 2024
• SC 13G Filing — SC 13G · Oct 25, 2024
• Inhibikase Therapeutics Files 8-K on Agreements and Personnel Changes — 8-K · Oct 22, 2024 Risk: medium
  Inhibikase Therapeutics, Inc. filed an 8-K on October 21, 2024, reporting on the entry into a material definitive agreement, the departure of directors or offic
• SC 13G Filing — SC 13G · Oct 17, 2024
• SC 13G Filing — SC 13G · Oct 17, 2024
• Inhibikase Therapeutics Announces CMO Departure, Interim Appointment — 8-K · Oct 10, 2024 Risk: medium
  On October 9, 2024, Inhibikase Therapeutics, Inc. announced the departure of Dr. Jonathan P. S. Walsh as Chief Medical Officer and the appointment of Dr. Michae
• SC 13G Filing — SC 13G · Oct 10, 2024
• Inhibikase Therapeutics Files 8-K — 8-K · Oct 9, 2024 Risk: low
  Inhibikase Therapeutics, Inc. filed an 8-K on October 9, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not c
• Inhibikase Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 14, 2024 Risk: medium
  Inhibikase Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its busines
• Inhibikase Therapeutics Files 8-K on Shareholder Votes — 8-K · Aug 6, 2024 Risk: low
  Inhibikase Therapeutics, Inc. filed an 8-K on August 5, 2024, to report on matters submitted to a vote of its security holders. The filing details the company's
• Inhibikase Therapeutics Files Additional Proxy Materials — DEFA14A · Jun 21, 2024 Risk: low
  Inhibikase Therapeutics, Inc. filed a Definitive Additional Materials (DEFA14A) on June 21, 2024. This filing is related to their proxy statement and indicates
• Inhibikase Therapeutics Files Definitive Proxy Statement — DEF 14A · Jun 20, 2024 Risk: low
  Inhibikase Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on June 20, 2024, for its annual meeting scheduled for August 5, 2024. The filing c
• Inhibikase Therapeutics Files S-1 Registration — S-1 · Jun 18, 2024 Risk: medium
  Inhibikase Therapeutics, Inc. filed an S-1 registration statement on June 18, 2024, to register an unspecified number of securities. The company, headquartered
• Inhibikase Therapeutics Reports on Shareholder Vote Matters — 8-K · Jun 10, 2024 Risk: low
  Inhibikase Therapeutics, Inc. filed an 8-K on June 10, 2024, reporting on a submission of matters to a vote of security holders that occurred on June 7, 2024. T
• Inhibikase Therapeutics Files 8-K with Material Agreements — 8-K · May 20, 2024 Risk: medium
  On May 20, 2024, Inhibikase Therapeutics, Inc. entered into a material definitive agreement, likely related to its business operations. The company also disclos
• Inhibikase Therapeutics Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 15, 2024 Risk: medium
  Inhibikase Therapeutics, Inc. (IKT) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Inhibikase Therapeutics, Inc. filed a 10-Q report for the quar
• Inhibikase Therapeutics Files Amendment to S-1 Registration Statement — S-1/A · May 9, 2024 Risk: low
  Inhibikase Therapeutics, Inc. (IKT) filed a Amended IPO Registration (S-1/A) with the SEC on May 9, 2024. Inhibikase Therapeutics, Inc. filed an S-1/A (Amendmen
• Inhibikase Therapeutics Files 8-K — 8-K · Apr 30, 2024 Risk: low
  Inhibikase Therapeutics, Inc. filed an 8-K on April 30, 2024, reporting events as of April 26, 2024. The filing includes information related to Regulation FD di
• Inhibikase Therapeutics Files S-1/A Amendment — S-1/A · Apr 29, 2024 Risk: medium
  Inhibikase Therapeutics, Inc. filed an S-1/A amendment on April 29, 2024, for its registration statement. The company, headquartered in Atlanta, GA, is focused
• Inhibikase Therapeutics Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 26, 2024 Risk: low
  Inhibikase Therapeutics, Inc. (IKT) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. The 2024 Annual Meeting of Stockholders for Inhibikase The
• Inhibikase Therapeutics Files Amendment to S-1 Registration Statement — S-1/A · Apr 25, 2024 Risk: low
  Inhibikase Therapeutics, Inc. (IKT) filed a Amended IPO Registration (S-1/A) with the SEC on April 25, 2024. Inhibikase Therapeutics, Inc. filed an amendment (S
• Inhibikase Therapeutics Files S-1 Registration Statement — S-1 · Apr 19, 2024 Risk: low
  Inhibikase Therapeutics, Inc. (IKT) filed a IPO Registration (S-1) with the SEC on April 19, 2024. Inhibikase Therapeutics, Inc. filed an S-1 registration state
• Inhibikase Therapeutics Files 8-K/A Amendment — 8-K/A · Apr 2, 2024 Risk: low
  Inhibikase Therapeutics, Inc. filed an amendment (8-K/A) on April 2, 2024, to a previous report originally dated January 16, 2024. This amendment pertains to th
• Inhibikase Therapeutics Files 2023 Annual Report on Form 10-K — 10-K · Mar 27, 2024 Risk: medium
  Inhibikase Therapeutics, Inc. (IKT) filed a Annual Report (10-K) with the SEC on March 27, 2024. Inhibikase Therapeutics, Inc. filed its annual report on Form 1

Risk Profile

Risk Assessment: Of IKT's 41 recent filings, 3 were flagged as high-risk, 18 as medium-risk, and 20 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Inhibikase Therapeutics, INC.'s most recent 10-K filing (Mar 26, 2026):

• Revenue: $0
• Net Income: -$20.6 million
• EPS: -$0.20
• Debt-to-Equity: 0.0
• Cash Position: $10.3 million
• Operating Margin: N/A
• Total Assets: $27.5 million
• Total Debt: $0

Key Executives

• Dr. Jonathan P. S. Walsh
• Dr. Michael J. O'Neill
• Milton H. Werner, Ph.D.

Industry Context

The Pulmonary Arterial Hypertension (PAH) market is a significant and growing therapeutic area, projected to reach $8.3 billion in 2025 with a CAGR of 3.3% through 2034. The landscape includes established treatments and newer therapies like sotatercept (WINREVAIR), which generated $1.44 billion in revenue in 2025, indicating strong market demand and commercial potential. Inhibikase Therapeutics aims to capture a share of this market with IKT-001, a differentiated oral therapy.

Top Tags

sec-filing (8) · corporate-governance (7) · Biotechnology (6) · financials (5) · biotech (5) · Inhibikase Therapeutics (5) · 8-K (4) · shareholder-vote (4) · proxy-statement (4) · 10-Q (4)

Key Numbers

• File Number: 333-294657 — This is the SEC file number associated with the S-8 registration statement.
• aggregate market value of common stock held by non-affiliates: $127.3 million — as of June 30, 2025
• shares of common stock outstanding: 132,032,636 — as of March 20, 2026
• patent protection for IKT-001: 2039 — until this year, with potential extension to 2044
• estimated global PAH market size: $8.3 billion — in 2025
• compound annual growth rate: 3.3% — for global PAH market through 2034
• revenue generated by sotatercept (WINREVAIR): $1.44 billion — in 2025
• approximate number of sites: 180 — for the IMPROVE-PAH Phase 3 study
• patients in Part A of IMPROVE-PAH: 140 — double blind, placebo-controlled study
• patients in Part B of IMPROVE-PAH: 346 — primary endpoint 6-minute walk distance
• SEC File Number: 001-39676 — Identifies the company's filing with the SEC.
• IRS Employer Identification No.: 26-3407249 — Company's tax identification number.
• Net Loss: $35,524,538 — For the nine months ended September 30, 2025, a 130% increase from $15,387,309 in 2024.
• Research and Development Expenses: $23,434,243 — For the nine months ended September 30, 2025, up from $10,016,982 in 2024.
• Selling, General and Administrative Expenses: $16,780,525 — For the nine months ended September 30, 2025, up from $5,643,386 in 2024.

Related Companies

IKAS · MRK · INHI · IKASE · IBK

Frequently Asked Questions